Document is current

Any future updates will be listed below

Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial

Crossref DOI link: https://doi.org/10.1007/s13555-021-00554-4

Published Online: 2021-05-31

Published Print: 2021-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark